BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - BOERSE MUENCHEN 01:15:54 31/05/2024 am IST | ||
| 1,201 EUR | +1.10% |
|
| Current month | +11.93% | ||
| 1 month | +11.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 30/24/30 | 1,201 | +1.10% |
| 29/24/29 | 1,188 | +1.31% |
| 28/24/28 | 1,172 | -1.69% |
| 27/24/27 | 1,192 | +0.60% |
| 24/24/24 | 1,185 | +1.27% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3T9Z |
| ISIN | DE000HD3T9Z7 |
| Date issued | 18/03/2024 |
| Strike | 1,400 $ |
| Maturity | 20/09/2024 (113 Days) |
| Parity | 1 : 1 |
| Emission price | 943.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,210 € |
|---|---|
| Lowest since issue | 820.4 € |
| Spread | 1.15 € |
| Spread % | 0.10% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
815.5
USD
Average target price
852.5
USD
Spread / Average Target
+4.53%
- Stock Market
- Certificates
- Certificat
